Download
journal.pone.0322003.pdf 744,51KB
WeightNameValue
1000 Titel
  • A cross-sectional study on the endorsement of reporting guidelines and clinical trial registration among immunology and allergy journals
1000 Autor/in
  1. Khan, Adam |
  2. Smith, Tim |
  3. Chaudhry, Asaad |
  4. Smith, Caleb A. |
  5. Nees, Danya |
  6. Hughes, Griffin |
  7. Rowsey, Kaylyn |
  8. Vassar, Matt |
1000 Erscheinungsjahr 2025
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2025-05-07
1000 Erschienen in
1000 Quellenangabe
  • 20(5):e0322003
1000 Copyrightjahr
  • 2025
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0322003 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057991/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Healthcare practitioners rely on research based on solid evidence for their clinical decisions, ensuring the provision of safe and effective patient care. The use of reporting guidelines and the registration of clinical trials enhance the reliability and credibility of research findings by promoting transparency and minimizing potential biases. However, it remains uncertain to what extent leading immunology and allergy journals have embraced these tools. This study aims to evaluate how commonly reporting guidelines and clinical trial registration are required and endorsed within leading immunology and allergy journals. METHODS: We identified the top 100 journals in the subcategory of “Immunology and Allergy” using the Scopus CiteScore tool for the year 2021. We thoroughly reviewed the “Instructions for Authors” section of each journal, focusing on indications related to specific reporting guidelines as outlined by the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network, as well as the practice of clinical trial registration. Our documentation categorized statements as “Not Mentioned,” “Recommended,” “Not Accepted,” or “Required.” The category “Not Accepted” specifically indicated that the journal explicitly did not accept the study designs associated with certain reporting guidelines, rather than implying bias against these guidelines. ensure equitable evaluation, we communicated with each journal to confirm the types of articles they accepted. RESULTS: Among the 100 journals assessed, the CONSORT guideline emerged as the most frequently cited, with 60 journals recommending adherence and 13 requiring it. Conversely, the QUOROM guideline was the least commonly cited, with merely two journals recommending its adherence and none requiring it. Nineteen journals did not reference a single reporting guideline. Remarkably, clinical trial registration was required by 42 journals and recommended by 34. CONCLUSION: This study reveals variation in the adoption of reporting guidelines and clinical trial registration in immunology and allergy journals. While some journals strongly advocate for or require these practices, others do not emphasize them at all. This inconsistency affects research rigor and reproducibility, highlighting the need for stricter enforcement. Editors should encourage these practices to enhance transparency and minimize biases.
1000 Sacherschließung
lokal Immunology
lokal Clinical trials
lokal Medical journals
lokal Allergies
lokal Clinical trial reporting
lokal Europe
lokal North America
lokal Research reporting guidelines
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1358-5119|https://frl.publisso.de/adhoc/uri/U21pdGgsIFRpbQ==|https://frl.publisso.de/adhoc/uri/Q2hhdWRocnksIEFzYWFk|https://frl.publisso.de/adhoc/uri/U21pdGgsIENhbGViIEEu|https://frl.publisso.de/adhoc/uri/TmVlcywgRGFueWE=|https://frl.publisso.de/adhoc/uri/SHVnaGVzLCBHcmlmZmlu|https://frl.publisso.de/adhoc/uri/Um93c2V5LCBLYXlseW4=|https://frl.publisso.de/adhoc/uri/VmFzc2FyLCBNYXR0
1000 (Academic) Editor
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6511238.rdf
1000 Erstellt am 2025-05-09T09:30:25.645+0200
1000 Erstellt von 337
1000 beschreibt frl:6511238
1000 Bearbeitet von 337
1000 Zuletzt bearbeitet 2025-08-26T14:01:23.202+0200
1000 Objekt bearb. Fri May 09 09:31:02 CEST 2025
1000 Vgl. frl:6511238
1000 Oai Id
  1. oai:frl.publisso.de:frl:6511238 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source